期刊文献+

Nintedanib对Ang Ⅱ诱导肾脏成纤维细胞产生细胞外基质的拮抗作用 被引量:1

Nintedanib suppresses overexpression of extracellular matrix induced by angiotensin Ⅱ in renal fibroblasts
下载PDF
导出
摘要 目的探讨尼达尼布(Nintedanib)对抗血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)诱导的肾脏成纤维细胞产生细胞外基质的作用及其机制。方法 AngⅡ处理大鼠肾脏成纤维细胞(NRK-49F),Western印迹法检测相关分子的蛋白表达量,DHE荧光探针法检测活性氧簇(ROS)的水平。结果肾脏成纤维细胞中AngⅡ通过诱导PI3K/Akt信号通路的激活,引起纤维连接蛋白和胶原蛋白Ⅰ的积聚。Nintedanib能抑制AngⅡ诱导的PI3K/Akt信号通路的激活。Nintedanib还可以抑制AngⅡ引起的ROS水平升高。结论 Nintedanib可以抑制AngⅡ诱导的ECM成分升高,其作用机制与其抑制PI3K/Akt激活并抑制ROS产生有关。 Objective To investigate the effect of nintedanib on extracellular matrix production induced by angiotensin I[ ( Ang 11 ) in renal fibroblasts and related mechanism. Methods Renal fibroblast cells were treated with Ang Ⅱ. Expression of fibronectin, collagen I levels was determined by Western blotting, and the ROS level was detected by DHE fluorescent probe. Results Ang Ⅱ induced the phosphorylation of PI3 K./Akt signalling, with the accumulation of fibronectin and collagen I in renal fibroblast cells. Nintedanib blocked the phosphorylation of Akt and attenuated the increase of fibronectin and collagen I induced by AngⅡ. Nintedanib also inhibited Ang Ⅱ induced ROS generation. Conclusion Nintedanib can attenuate the accumulation of ECM proteins induced by Ang Ⅱ, which may be associated with the suppression effect on PI3K/Akt signalling activation and subsequent ROS overproduction.
作者 王艳道 余晨
出处 《同济大学学报(医学版)》 CAS 2015年第4期13-18,共6页 Journal of Tongji University(Medical Science)
基金 国家自然科学基金(81370790)
关键词 尼达尼布 PI3K/AKT 活性氧簇 血管紧张素Ⅱ 肾脏纤维化 大鼠 Nintedanib PI3K/Akt reactive oxygen species angiotensin Ⅱ renal fibrosis rat
  • 相关文献

参考文献12

  • 1Liu GX, Li YQ, Huang XR, et al. Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Spl-TGF-beta/Smad3-NF. kappaB- dependent mechanisms in mice[ J]. PLoS One, 2013, 8 ( 1 ) : e53573.
  • 2Hilberg F, Roth G J, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy [ J ]. Cancer Res, 2008,68(12) : 4774 -4782.
  • 3Eisen T, Shparyk Y, Macleod N, et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study [ J ]. Invest New Drugs, 2013,31 (5) : 1283 -1293.
  • 4Vergote I. Novel therapies, including enzastaurin, in the treatment of ovarian cancer [ J ]. Expert Opin Investig Drugs, 2014,23(5) : 579-598.
  • 5Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis[J]. J Pharmacol Exp Ther, 2014,349 (2): 209 - 220.
  • 6Hostettler KE, Zhong J, Papakonstantinou E, et al.Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis [J]. RespirRes, 2014,15(1): 157.
  • 7Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis[J]. J Pharmacol Exp Ther, 2014,349(2): 209 - 220.
  • 8Wang J, Chu ES, Chen HY, et al. microRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway [ J ]. Oncotarget, 2015,6 ( 9 ) : 7325 - 7338.
  • 9Runyan CE, Schnaper HW, Poncelet AC. The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-betal [ J ]. J Biol Chem, 2004,279 (4) : 2632 - 2639.
  • 10Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: molecular targets for anti-cancer drug development [ J ]. Curr Cancer Drug Targets, 2004,4 (3) : 235 - 256.

同被引文献6

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部